Design of sequentially randomized trials for testing adaptive treatment strategies

被引:18
作者
Ogbagaber, Semhar B. [1 ]
Karp, Jordan [2 ]
Wahed, Abdus S. [1 ]
机构
[1] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Western Psychiat Inst & Clin, Sch Med, Pittsburgh, PA 15213 USA
关键词
sample size; power; sequential multiple assignment randomized trial (SMART); adaptive treatment strategy (ATS); SAMPLE-SIZE; 2-STAGE; INFERENCE; DISEASE;
D O I
10.1002/sim.6747
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
An adaptive treatment strategy (ATS) is an outcome-guided algorithm that allows personalized treatment of complex diseases based on patients' disease status and treatment history. Conditions such as AIDS, depression, and cancer usually require several stages of treatment because of the chronic, multifactorial nature of illness progression and management. Sequential multiple assignment randomized (SMAR) designs permit simultaneous inference about multiple ATSs, where patients are sequentially randomized to treatments at different stages depending upon response status. The purpose of the article is to develop a sample size formula to ensure adequate power for comparing two or more ATSs. Based on a Wald-type statistic for comparing multiple ATSs with a continuous endpoint, we develop a sample size formula and test it through simulation studies. We show via simulation that the proposed sample size formula maintains the nominal power. The proposed sample size formula is not applicable to designs with time-to-event endpoints but the formula will be useful for practitioners while designing SMAR trials to compare adaptive treatment strategies. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:840 / 858
页数:19
相关论文
共 19 条
[1]   Efficient design and inference for multistage randomized trials of individualized treatment policies [J].
Dawson, Ree ;
Lavori, Philip W. .
BIOSTATISTICS, 2012, 13 (01) :142-152
[2]   Sample size calculations for evaluating treatment policies in multi-stage designs [J].
Dawson, Ree ;
Lavori, Philip W. .
CLINICAL TRIALS, 2010, 7 (06) :643-652
[3]   ANALYSIS OF VARIANCE AND MAGNITUDE OF EFFECTS - GENERAL APPROACH [J].
DWYER, JH .
PSYCHOLOGICAL BULLETIN, 1974, 81 (10) :731-737
[4]   Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome [J].
Estey, EH ;
Thall, PF ;
Pierce, S ;
Cortes, J ;
Beran, M ;
Kantarjian, H ;
Keating, MJ ;
Andreeff, M ;
Freireich, E .
BLOOD, 1999, 93 (08) :2478-2484
[5]   Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies [J].
Feng, Wentao ;
Wahed, Abdus S. .
BIOMETRIKA, 2008, 95 (03) :695-707
[6]   Sample size for two-stage studies with maintenance therapy [J].
Feng, Wentao ;
Wahed, Abdus S. .
STATISTICS IN MEDICINE, 2009, 28 (15) :2028-2041
[7]   Weighted log-rank statistic to compare shared-path adaptive treatment strategies [J].
Kidwell, Kelley M. ;
Wahed, Abdus S. .
BIOSTATISTICS, 2013, 14 (02) :299-312
[8]   Up-front versus sequential randomizations for inference on adaptive treatment strategies [J].
Ko, Jin H. ;
Wahed, Abdus S. .
STATISTICS IN MEDICINE, 2012, 31 (09) :812-830
[9]  
Lavori Philip W, 2004, Clin Trials, V1, P9, DOI 10.1191/1740774S04cn002oa
[10]   Flexible treatment strategies in chronic disease: Clinical and research implications [J].
Lavori, PW ;
Dawson, R ;
Rush, AJ .
BIOLOGICAL PSYCHIATRY, 2000, 48 (06) :605-614